IN211493B - - Google Patents

Info

Publication number
IN211493B
IN211493B IN127MUN2001A IN211493B IN 211493 B IN211493 B IN 211493B IN 127MUN2001 A IN127MUN2001 A IN 127MUN2001A IN 211493 B IN211493 B IN 211493B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Teddy Halmos
Bruno Simoneau
Montse Llinas-Brunet
Marc-Andre Poupart
Jean Rancourt
Nathalie Goudreau
Dale Cameron
Murray D Bailey
Elise Ghiro
Dominik Wernic
Anne Marie Faucher
Youla S Tsantrizos
Original Assignee
Boehringer Ingelheim Ca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Ca Ltd filed Critical Boehringer Ingelheim Ca Ltd
Publication of IN211493B publication Critical patent/IN211493B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN127MUN2001 1998-08-10 1999-08-09 IN211493B (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9593198P 1998-08-10 1998-08-10
US13238699P 1999-05-04 1999-05-04

Publications (1)

Publication Number Publication Date
IN211493B true IN211493B (enExample) 2008-01-25

Family

ID=26790767

Family Applications (3)

Application Number Title Priority Date Filing Date
IN127MUN2001 IN211493B (enExample) 1998-08-10 1999-08-09
IN127MU2001 IN2001MU00127A (enExample) 1998-08-10 2001-02-07
IN706MU2007 IN2007MU00706A (enExample) 1998-08-10 2007-05-11

Family Applications After (2)

Application Number Title Priority Date Filing Date
IN127MU2001 IN2001MU00127A (enExample) 1998-08-10 2001-02-07
IN706MU2007 IN2007MU00706A (enExample) 1998-08-10 2007-05-11

Country Status (43)

Country Link
US (11) US6323180B1 (enExample)
EP (2) EP1105413B1 (enExample)
JP (2) JP4485685B2 (enExample)
KR (2) KR100672229B1 (enExample)
CN (2) CN101143892B (enExample)
AR (3) AR020880A1 (enExample)
AT (1) ATE430158T1 (enExample)
AU (1) AU769738B2 (enExample)
BG (1) BG65738B1 (enExample)
BR (2) BR9917805B1 (enExample)
CA (2) CA2445938C (enExample)
CO (1) CO5261542A1 (enExample)
CY (2) CY1109291T1 (enExample)
CZ (2) CZ301268B6 (enExample)
DE (1) DE69940817D1 (enExample)
DK (2) DK1105413T3 (enExample)
EA (1) EA003906B1 (enExample)
EE (1) EE05517B1 (enExample)
ES (2) ES2405930T3 (enExample)
HK (1) HK1040085B (enExample)
HR (1) HRP20010102B1 (enExample)
HU (2) HU229262B1 (enExample)
ID (1) ID27839A (enExample)
IL (3) IL141012A0 (enExample)
IN (3) IN211493B (enExample)
ME (1) ME00381B (enExample)
MX (2) MX257413B (enExample)
MY (1) MY127538A (enExample)
NO (2) NO328952B1 (enExample)
NZ (1) NZ510396A (enExample)
PE (1) PE20000949A1 (enExample)
PH (1) PH11999002002B1 (enExample)
PL (1) PL204850B1 (enExample)
PT (2) PT1105413E (enExample)
RS (3) RS50798B (enExample)
SA (1) SA99200617B1 (enExample)
SI (2) SI2028186T1 (enExample)
SK (2) SK288068B6 (enExample)
TR (2) TR200200129T2 (enExample)
TW (1) TWI250165B (enExample)
UA (1) UA75026C2 (enExample)
WO (1) WO2000009543A2 (enExample)
ZA (1) ZA200100971B (enExample)

Families Citing this family (423)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN183120B (enExample) 1996-10-18 1999-09-11 Vertex Pharma
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
WO2001000843A2 (en) * 1999-06-25 2001-01-04 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding metabolic pathway proteins
NZ521455A (en) 2000-04-05 2004-06-25 Schering Corp Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising N-Cyclic P2 Moieties
BR0110104A (pt) 2000-04-19 2003-01-07 Schering Corp Inibidores de ns-3 serina rotease macrocìclica do vìrus da hepatite c compreendendo porções de alquil e aril alanina p2
EP1278743A4 (en) * 2000-05-05 2003-05-14 Smithkline Beecham Corp NEW ANTI-INFECTIOUS ACTIVE SUBSTANCES
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
WO2002008187A1 (en) 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
MY139078A (en) 2000-07-21 2009-08-28 Schering Corp Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR034127A1 (es) * 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
CN100391967C (zh) * 2000-11-20 2008-06-04 布里斯托尔-迈尔斯斯奎布公司 丙型肝炎三肽抑制剂
EP1343807B1 (en) 2000-12-12 2009-04-29 Schering Corporation Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
JP2004532184A (ja) 2001-01-22 2004-10-21 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
EP1404704B9 (en) 2001-07-11 2008-02-20 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
WO2003024747A1 (en) 2001-09-14 2003-03-27 Honda Giken Kogyo Kabushiki Kaisha Front grill impact-absorbing structure for a vehicle
WO2003035060A1 (en) 2001-10-24 2003-05-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
US20050009873A1 (en) * 2001-11-02 2005-01-13 Gianpaolo Bravi Acyl dihydro pyrrole derivatives as hcv inhibitors
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
TWI265927B (en) 2002-01-23 2006-11-11 Schering Corp Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7273885B2 (en) 2002-04-11 2007-09-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ATE481106T1 (de) * 2002-05-20 2010-10-15 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
DE60336550D1 (de) * 2002-05-20 2011-05-12 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
WO2004043339A2 (en) * 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
KR100457857B1 (ko) * 2002-05-23 2004-11-18 (주) 비엔씨바이오팜 2-[2-(3-인돌릴)에틸아미노]피리딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물
CA2490191C (en) 2002-06-28 2010-08-03 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside prodrugs for treating flaviviridae infections
US20040033959A1 (en) * 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
AU2003264038A1 (en) * 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
EP1408031A1 (en) * 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidine derivatives useful in treatment of hepatitis C virus infection
BR0315417A (pt) 2002-10-24 2005-08-16 Glaxo Group Ltd Derivados 1-acil-pirrolidina para o tratamento de infecções virais
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
CA2516018C (en) * 2003-03-05 2011-08-23 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
WO2004101605A1 (en) * 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
KR100960802B1 (ko) * 2003-03-08 2010-06-01 주식회사유한양행 씨형 간염바이러스 감염 치료용 엔에스3 프로테아제 억제제
US7148347B2 (en) * 2003-04-10 2006-12-12 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
JP4733023B2 (ja) * 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
PL1615613T3 (pl) 2003-04-18 2010-04-30 Enanta Pharm Inc Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C
US6846836B2 (en) 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
AU2004240704B9 (en) * 2003-05-21 2009-10-22 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor compounds
KR100883703B1 (ko) * 2003-05-30 2009-02-12 파마셋 인코포레이티드 변형 불소화 뉴클레오시드 유사체
WO2004113365A2 (en) * 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7273851B2 (en) * 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
KR20060084845A (ko) * 2003-07-25 2006-07-25 이데닉스 (케이만) 리미티드 Ｃ형 간염을 포함하는 플라비비리다에를 치료하기 위한퓨린 뉴클레오시드 유사체
CA2536570A1 (en) 2003-08-26 2005-03-10 Schering Corporation Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
US7642235B2 (en) * 2003-09-22 2010-01-05 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7592419B2 (en) 2003-09-26 2009-09-22 Schering Corporation Macrocyclic inhibitors of hepatitis C virus NS3-serine protease
EP1692157B1 (en) 2003-10-10 2013-04-17 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
OA13315A (en) 2003-10-14 2007-04-13 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
CA2551074A1 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2007532479A (ja) * 2003-11-20 2007-11-15 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼの脱ペプチド化インヒビター
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
EP1699558B1 (en) * 2003-12-08 2009-03-11 Boehringer Ingelheim International GmbH Removal of ruthenium by-product by supercritical fluid processing
WO2005058884A2 (en) 2003-12-15 2005-06-30 Japan Tobacco Inc. Cyclopropane compounds and pharmaceutical use thereof
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
CA2549851C (en) 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
SE0400199D0 (sv) * 2004-01-30 2004-01-30 Medivir Ab HCV Protease inhbitors
UA84050C2 (en) * 2004-01-30 2008-09-10 Медивир Аб Hcv ns-3-serine protease inhibitors
EP1711515A2 (en) 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
RS52931B (sr) 2004-02-20 2014-02-28 Boehringer Ingelheim International Gmbh Inhibitori virusne polimeraze
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
TW200602037A (en) 2004-02-27 2006-01-16 Schering Corp Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
ATE470660T1 (de) * 2004-02-27 2010-06-15 Schering Corp Schwefelverbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
RU2006134002A (ru) 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
JP4745327B2 (ja) 2004-02-27 2011-08-10 シェーリング コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
EP1737821B1 (en) 2004-02-27 2009-08-05 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2005085197A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
KR101135765B1 (ko) * 2004-03-12 2012-04-23 버텍스 파마슈티칼스 인코포레이티드 아스파르트산 아세탈 카스파아제 억제제의 제조를 위한방법 및 중간체
JP4654239B2 (ja) * 2004-03-15 2011-03-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウィルス感染症の治療に適した大環状ジペプチドの調製方法
EA012389B1 (ru) * 2004-03-30 2009-10-30 Интермун, Инк. Макроциклические соединения в качестве ингибиторов вирусной репликации
CN1980657A (zh) 2004-05-05 2007-06-13 耶鲁大学 新颖的抗病毒赛菊宁黄质类似物
WO2005113581A1 (en) 2004-05-20 2005-12-01 Schering Corporation Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
US7514557B2 (en) * 2004-05-25 2009-04-07 Boehringer Ingelheim International Gmbh Process for preparing acyclic HCV protease inhibitors
US7534767B2 (en) 2004-06-15 2009-05-19 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
US20070265222A1 (en) 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
WO2006000085A1 (en) * 2004-06-28 2006-01-05 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
CA2571984C (en) * 2004-07-16 2012-04-10 Gilead Sciences, Inc. Antiviral compounds
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
JP4914355B2 (ja) * 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
MX2007002371A (es) 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
EP3109244B1 (en) * 2004-09-14 2019-03-06 Gilead Pharmasset LLC Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
WO2006030892A1 (ja) * 2004-09-17 2006-03-23 Nippon Shinyaku Co., Ltd. 複素環化合物の製造方法
TW200621233A (en) 2004-10-01 2006-07-01 Vertex Pharma HCV NS3-NS4A protease inhibition
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7323447B2 (en) * 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ562167A (en) 2005-03-08 2011-01-28 Boehringer Ingelheim Int Process for preparing macrocyclic compounds
US7879797B2 (en) * 2005-05-02 2011-02-01 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7592336B2 (en) * 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ563909A (en) 2005-05-13 2011-10-28 Virochem Pharma Inc Thiophene derivatives and their use for the treatment or prevention of flavivirus infections
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
NZ563361A (en) 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
EP1919478B1 (en) * 2005-06-02 2016-03-23 Merck Sharp & Dohme Corp. Combination of hcv protease inhibitors with a surfactant
EP1893211B1 (en) 2005-06-17 2011-09-14 Novartis AG Use of sanglifehrin in hcv
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
ZA200711069B (en) * 2005-06-30 2009-03-25 Virobay Inc HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7470664B2 (en) * 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
US20080200497A1 (en) * 2005-07-20 2008-08-21 Bailey Murray D Hepatitis C Inhibitor Peptide Analogs
BRPI0613962A2 (pt) * 2005-07-25 2009-03-24 Intermune Inc inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c
WO2007014924A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
DK1919904T3 (da) 2005-07-29 2014-04-07 Janssen R & D Ireland Makrocykliske inhibitorer af hepatitis-c-virus
MY139923A (en) 2005-07-29 2009-11-30 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
CN101273042B (zh) * 2005-07-29 2013-11-06 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
CA2617099C (en) 2005-07-29 2014-03-25 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
MY144607A (en) 2005-07-29 2011-10-14 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
AU2006275605B2 (en) * 2005-08-01 2011-01-06 Merck Sharp & Dohme Corp. Macrocyclic peptides as HCV NS3 protease inhibitors
WO2007016589A2 (en) * 2005-08-02 2007-02-08 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP1915054A4 (en) 2005-08-09 2010-09-01 Merck Sharp & Dohme CYCLIC ACETAL DERIVATIVES OF RIBONUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS
CA2618682C (en) 2005-08-12 2011-06-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
BRPI0615029A2 (pt) 2005-08-19 2009-06-16 Vertex Pharma processos e intermediários
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CA2621360C (en) 2005-09-09 2013-12-24 Boehringer Ingelheim International Gmbh Ring-closing metathesis process for the preparation of macrocyclic peptides
DK1999129T3 (da) 2005-10-11 2011-02-07 Intermune Inc Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
JP5409008B2 (ja) 2005-11-11 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス改変体
ES2378473T3 (es) * 2005-12-21 2012-04-12 Abbott Laboratories Compuestos antivirales
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
RU2467007C2 (ru) 2005-12-21 2012-11-20 Эбботт Лэборетриз Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2340836A1 (en) 2006-02-27 2011-07-06 Vertex Pharmceuticals Incorporated Co-crystals comprising VX-950 and their pharmaceutical compositions
AU2007223797A1 (en) 2006-03-08 2007-09-13 Achillion Pharmaceuticals, Inc. Substituted aminothiazole derivatives with anti-HCV activity
NZ571280A (en) 2006-03-16 2011-10-28 Vertex Pharma Deuterated hepatitis C protease inhibitors
US7825152B2 (en) 2006-04-11 2010-11-02 Novartis Ag Organic compounds and their uses
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US7951823B2 (en) 2006-05-23 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
US7728148B2 (en) * 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US20080187516A1 (en) * 2006-06-06 2008-08-07 Ying Sun Acyclic oximyl hepatitis c protease inhibitors
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
GB0612423D0 (en) * 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
AR061629A1 (es) * 2006-06-26 2008-09-10 Enanta Pharm Inc Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
WO2008022006A2 (en) * 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US20080038225A1 (en) * 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
MX2009000882A (es) 2006-08-17 2009-02-04 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
WO2008063727A2 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
CA2667165A1 (en) * 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
CA2667146C (en) * 2006-10-24 2016-01-19 Merck & Co., Inc. Hcv ns3 protease inhibitors
JP5345941B2 (ja) * 2006-10-24 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
ES2444575T3 (es) * 2006-10-27 2014-02-25 Merck Sharp & Dohme Corp. Inhibidores de la proteasa NS3 del VHC
US20100099695A1 (en) 2006-10-27 2010-04-22 Liverton Nigel J HCV NS3 Protease Inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
TW200827364A (en) * 2006-11-02 2008-07-01 Taigen Biotechnology Co Ltd HCV protease inhibitors
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2670260A1 (en) 2006-11-15 2008-05-22 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of flavivirus infections
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CL2007003299A1 (es) 2006-11-17 2008-08-22 Tibotec Pharm Ltd Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
US20100081672A1 (en) * 2006-12-07 2010-04-01 Schering Corporation Ph sensitive matrix formulation
JP2010513450A (ja) * 2006-12-20 2010-04-30 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス性インドール
US8236950B2 (en) * 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
GB0625349D0 (en) * 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625345D0 (en) * 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008074035A1 (en) * 2006-12-27 2008-06-19 Abbott Laboratories Hcv protease inhibitors and uses thereof
WO2008095058A1 (en) * 2007-02-01 2008-08-07 Taigen Biotechnology Co. Ltd. Hcv protease inhibitors
AU2008219704A1 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2463284A1 (en) 2007-02-27 2012-06-13 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CA2696053A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
JP2010522172A (ja) * 2007-03-23 2010-07-01 シェーリング コーポレイション Ｈｃｖｎｓ３プロテアーゼのｐ１−非エピメリ化ケトアミド阻害剤
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20080317712A1 (en) * 2007-04-26 2008-12-25 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
US20080292587A1 (en) * 2007-04-26 2008-11-27 Ying Sun Oximyl dipeptide hepatitis c protease inhibitors
US7910587B2 (en) * 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
US20080267917A1 (en) * 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
EP2160392A2 (en) * 2007-05-03 2010-03-10 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
NZ580917A (en) 2007-05-04 2012-06-29 Vertex Pharma Combinations of protease inhibitors such as VX-950 and polymerase inhibitors for the treatment of HCV infection
KR20090130347A (ko) * 2007-05-09 2009-12-22 화이자 인코포레이티드 치환된 헤테로사이클릭 유도체 및 조성물 및 항균제로서의 이의 약학적 용도
BRPI0811447A2 (pt) * 2007-05-10 2014-10-29 Intermune Inc Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
TW200914013A (en) * 2007-06-29 2009-04-01 Gilead Sciences Inc Antiviral compounds
KR101596524B1 (ko) * 2007-06-29 2016-02-22 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
CN101754970B (zh) * 2007-07-17 2013-07-10 P.安杰莱蒂分子生物学研究所 用于治疗丙型肝炎的大环吲哚衍生物
WO2009010804A1 (en) * 2007-07-19 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic compounds as antiviral agents
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
AU2008297015B2 (en) 2007-08-30 2013-08-22 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
WO2009055335A2 (en) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
JP2011503201A (ja) 2007-11-14 2011-01-27 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状テトラゾリルｃ型肝炎セリンプロテアーゼ阻害剤
WO2009070689A1 (en) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
WO2009070692A1 (en) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
JP5529036B2 (ja) * 2007-12-05 2014-06-25 エナンタ ファーマシューティカルズ インコーポレイテッド フッ素化トリペプチドｈｃｖセリンプロテアーゼ阻害剤
WO2009076166A2 (en) * 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Oximyl hcv serine protease inhibitors
CA2708047A1 (en) 2007-12-06 2009-06-11 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis c protease inhibitors
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8101567B2 (en) * 2008-01-24 2012-01-24 Enanta Pharmaceuticals, Inc. Heteroaryl-containing tripeptide HCV serine protease inhibitors
US8501682B2 (en) * 2008-01-24 2013-08-06 Enanta Pharmaceuticals, Inc. Difluorinated tripeptides as HCV serine protease inhibitors
AR070413A1 (es) 2008-02-04 2010-04-07 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de proteasa de serina
CA2713108A1 (en) * 2008-02-07 2009-08-13 Virobay, Inc. Inhibitors of cathepsin b
EP2268285B1 (en) 2008-02-25 2018-06-27 Merck Sharp & Dohme Corp. Therapeutic compounds
US8372802B2 (en) * 2008-03-20 2013-02-12 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis C virus inhibitors
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
WO2009142842A2 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) * 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8461107B2 (en) * 2008-04-28 2013-06-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8211891B2 (en) * 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
US20090285774A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
CN102046648A (zh) 2008-05-29 2011-05-04 百时美施贵宝公司 丙型肝炎病毒抑制剂
US7964560B2 (en) * 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
KR20110065440A (ko) 2008-07-02 2011-06-15 아이데닉스 파마슈티칼스, 인코포레이티드 바이러스 감염의 치료를 위한 화합물 및 제약 조성물
SI2310095T1 (sl) 2008-07-22 2013-01-31 Merck Sharp & Dohme Corp. Makrocikliäśne kuinoksalinske spojine kot hcv ns3 proteazni inhibitorji
JP2011528686A (ja) 2008-07-23 2011-11-24 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式抗ウイルス性化合物
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
KR101653550B1 (ko) * 2008-09-16 2016-09-02 베링거 인겔하임 인터내셔날 게엠베하 강력한 ｈｃｖ 억제제인 2-티아졸릴-4-퀴놀리닐-옥시 유도체의 결정 형태
MX2011002602A (es) * 2008-09-17 2011-04-07 Boehringer Ingelheim Int Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina.
KR20110061640A (ko) 2008-09-26 2011-06-09 에프. 호프만-라 로슈 아게 Ｈｃｖ 치료용 피린 또는 피라진 유도체
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010039801A2 (en) 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
AU2009303483A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
WO2010049331A1 (en) 2008-10-30 2010-05-06 F. Hoffmann-La Roche Ag Heterocyclic antiviral arylpyridone derivatives
KR20110087297A (ko) * 2008-11-21 2011-08-02 베링거 인겔하임 인터내셔날 게엠베하 경구 투여용의 강력한 ｈｃｖ 억제제의 약제학적 조성물
PE20120124A1 (es) 2008-12-03 2012-03-17 Presidio Pharmaceuticals Inc Derivados 2-pirrolidin-3-il-1h-imidazol, como inhibidores de la proteina no estructural 5a del virus de la heptitis c
CA2750577A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US20100272674A1 (en) * 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR074670A1 (es) 2008-12-19 2011-02-02 Gilead Sciences Inc Inhibidores de la proteasa ns3 del vhc virus de la hepatitis c
US8178547B2 (en) 2008-12-22 2012-05-15 Roche Palo Alto Llc Heterocyclic antiviral compounds
EP2367813A1 (en) 2008-12-22 2011-09-28 Gilead Sciences, Inc. Antiviral compounds
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
CN102753563A (zh) 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8193372B2 (en) 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
CN102341382A (zh) 2009-03-06 2012-02-01 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
AU2010229795A1 (en) 2009-03-27 2011-10-13 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
WO2010118009A1 (en) * 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
CN102448936A (zh) 2009-04-25 2012-05-09 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
EP2429568B1 (en) 2009-05-13 2016-08-17 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
CN102803212A (zh) 2009-06-24 2012-11-28 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2011003063A2 (en) * 2009-07-02 2011-01-06 Dr. Reddy's Laboratories Ltd. Enzymes and methods for resolving amino vinyl cyclopropane carboxylic acid derivatives
AU2010270783B2 (en) 2009-07-07 2013-06-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition for a hepatitis C viral protease inhibitor
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
EP2461811B1 (en) 2009-08-05 2016-04-20 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US8742162B2 (en) 2009-08-10 2014-06-03 Sumitomo Chemical Company, Limited Method for producing optically active 1-amino-2-vinylcyclopropanecarboxylic acid ester
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
US8389560B2 (en) * 2009-09-15 2013-03-05 Taigen Biotechnology Co., Ltd. HCV protease inhibitors
JP2013505952A (ja) * 2009-09-28 2013-02-21 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新しい大環状阻害剤
US9193740B2 (en) * 2009-10-19 2015-11-24 Enanta Pharmaceuticals, Inc. Bismacrocyclic compounds as hepatitis C virus inhibitors
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
AU2010326225A1 (en) 2009-11-25 2012-06-07 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011079327A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US20110178107A1 (en) * 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
MX344373B (es) 2010-01-27 2016-12-13 Ab Pharma Ltd * Compuestos policiclicos heterociclicos se puede utilizar como inhibidores eficaces para virus de la hepatitis c.
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
WO2011119858A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
JP2013522377A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
WO2011119860A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
EA026341B9 (ru) 2010-03-31 2021-12-27 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Кристаллическая форма нуклеозидфосфорамидата
AR094621A1 (es) 2010-04-01 2015-08-19 Idenix Pharmaceuticals Inc Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
WO2011149856A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
US20130157258A1 (en) 2010-06-15 2013-06-20 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AU2011276526A1 (en) 2010-06-28 2013-01-10 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
EP2606041A2 (en) 2010-08-17 2013-06-26 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
DK2618831T3 (en) 2010-09-21 2016-04-04 Enanta Pharm Inc Macrocyclic prolinafledte HCV serine protease inhibitors
CN103228278A (zh) * 2010-09-30 2013-07-31 贝林格尔.英格海姆国际有限公司 治疗hcv感染的组合疗法
CA2811799A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
JP5906253B2 (ja) * 2010-12-16 2016-04-20 アッヴィ・インコーポレイテッド 抗ウイルス性化合物
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8962810B2 (en) 2011-06-16 2015-02-24 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
JPWO2012176715A1 (ja) 2011-06-21 2015-02-23 三菱瓦斯化学株式会社 １−アミノ−２−ビニルシクロプロパンカルボン酸アミドおよびその塩、ならびにその製造方法
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
CN102807607B (zh) * 2011-07-22 2013-10-23 爱博新药研发(上海)有限公司 抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
TW201313697A (zh) 2011-07-26 2013-04-01 Vertex Pharma 製備噻吩化合物之方法
DE102012016127A1 (de) 2011-08-31 2013-02-28 Daniel Elias Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
JP2014526474A (ja) 2011-09-12 2014-10-06 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
MX2014003705A (es) 2011-10-10 2014-07-22 Hoffmann La Roche Compuestos antivirales.
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
DE202012012956U1 (de) 2011-10-21 2014-10-16 Abbvie Inc. Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
WO2013074386A2 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP4556010A3 (en) 2011-11-30 2025-07-23 Emory University Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
PE20142102A1 (es) 2011-12-06 2015-01-04 Univ Leland Stanford Junior Metodos y composiciones para tratar enfermedades virales
KR20140104030A (ko) 2011-12-16 2014-08-27 에프. 호프만-라 로슈 아게 Hcv ns5a의 억제제
PT2794628T (pt) 2011-12-20 2017-07-05 Riboscience Llc Derivados nucleosídicos 4¿-azido-3¿-fluoro substituídos como inibidores de replicação de arn de vhc
PL2794629T3 (pl) 2011-12-20 2018-02-28 Riboscience Llc 2',4'-difluoro-2'-metylo-podstawione pochodne nukleozydowe jako inhibitory replikacji rna hcv
WO2013106344A1 (en) 2012-01-12 2013-07-18 Ligand Pharmaceuticals, Inc. 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
CN104244926A (zh) 2012-01-12 2014-12-24 勃林格殷格翰国际有限公司 作为强效的hcv 抑制剂的稳定的药物制剂
US20130217644A1 (en) 2012-02-13 2013-08-22 Idenix Pharmaceuticals, Inc. Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
BR112014015582A8 (pt) * 2012-02-24 2017-07-04 Hoffmann La Roche compostos antivirais
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
CN104470939B (zh) 2012-05-22 2017-04-26 埃迪尼克斯医药有限责任公司 用于肝脏疾病的d型氨基酸化合物
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
HK1207647A1 (en) 2012-10-08 2016-02-05 Idenix Pharmaceuticals Llc 2'-chloro nucleoside analogs for hcv infection
EP2909223B1 (en) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinucleotide compounds for hcv infection
HRP20161694T1 (hr) 2012-10-19 2017-03-10 Bristol-Myers Squibb Company 9-metil supstituirani heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4) diazaciklopentadecinil karbamat derivati kao ne-strukturalni 3 (ns3) proteazni inhibitori za liječenje infekcija virusom hepatitisa c
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
CN103804208B (zh) * 2012-11-14 2016-06-08 重庆博腾制药科技股份有限公司 一种丙肝药物中间体的制备方法
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
MX2015009176A (es) 2013-01-23 2015-11-09 Hoffmann La Roche Derivados de triazola antivirales.
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
HK1216885A1 (zh) 2013-03-05 2016-12-09 F. Hoffmann-La Roche Ag 抗病毒化合物
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
BR112015023343A2 (pt) * 2013-03-14 2017-07-18 Achillion Pharmaceuticals Inc método para preparar sovaprevir, método de preparar um composto da fórmula (c), método de preparação do composto f-2, composto, processo, método de preparação de uma forma amorfa pura de sovaprevir, e,forma cristalina de sovaprevir
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
NZ714927A (en) 2013-05-16 2020-09-25 Riboscience Llc 4’-fluoro-2’-methyl substituted nucleoside derivatives
JP2016519146A (ja) 2013-05-16 2016-06-30 リボサイエンス・エルエルシー ４’−アジド，３’−デオキシ−３’−フルオロ置換ヌクレオシド誘導体
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US9717797B2 (en) 2013-12-05 2017-08-01 International Business Machines Corporation Polycarbonates bearing aromatic N-heterocycles for drug delivery
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2015134780A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
TWI860279B (zh) 2017-09-21 2024-11-01 美商里伯賽恩斯有限責任公司 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物
JP7584418B2 (ja) 2018-12-04 2024-11-15 ブリストル－マイヤーズ スクイブ カンパニー 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475255A3 (en) * 1990-09-12 1993-04-14 F. Hoffmann-La Roche Ag Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
JPH05155827A (ja) * 1991-12-09 1993-06-22 Banyu Pharmaceut Co Ltd ｃｉｓ−２−アミノシクロプロパンカルボン酸誘導体の製造法
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
CN1141591A (zh) * 1994-02-23 1997-01-29 布·安格莱荻公司分子生物学研究所 体外再生丙型肝炎病毒(hcv)ns3蛋白酶的解蛋白活性的方法
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
IT1277914B1 (it) * 1995-08-22 1997-11-12 Angeletti P Ist Richerche Bio Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e
CA2165996C (en) * 1995-12-22 2002-01-29 Murray Douglas Bailey Stereoselective preparation of 2-substituted succinic derivatives
DE19600034C2 (de) 1996-01-02 2003-12-24 Degussa 1,1,2-Trisubstituierte Cyclopropanverbindungen, Verfahren zu deren Herstellung und Dihydroxyethyl-substituierte 1-Amino-cyclopropan-1-carbonsäure
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
IN183120B (enExample) 1996-10-18 1999-09-11 Vertex Pharma
CA2291778A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
SE9704543D0 (sv) * 1997-12-05 1997-12-05 Astra Ab New compounds
US6455571B1 (en) * 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
DE19835120C1 (de) * 1998-08-04 1999-10-21 Westfalia Separator Ag Verfahren und Vorrichtung zum Einstellen des Flüssigkeitsgehalts des aus einer selbstentleerenden Schleudertrommel eines Separators ausgetragenen Feststoffes
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2516018C (en) * 2003-03-05 2011-08-23 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
WO2004101605A1 (en) * 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds

Also Published As

Publication number Publication date
PT1105413E (pt) 2009-06-30
NO20010683L (no) 2001-04-02
JP2002522554A (ja) 2002-07-23
IL141012A0 (en) 2002-02-10
SK286994B6 (sk) 2009-09-07
CZ302766B6 (cs) 2011-10-26
HK1040085B (zh) 2008-05-30
YU9401A (sh) 2003-02-28
CZ2001516A3 (cs) 2001-08-15
IL196545A0 (en) 2011-07-31
US6329379B1 (en) 2001-12-11
US20020016442A1 (en) 2002-02-07
ES2405930T3 (es) 2013-06-04
MY127538A (en) 2006-12-29
CO5261542A1 (es) 2003-03-31
SK288068B6 (sk) 2013-05-03
RS50798B (sr) 2010-08-31
RS53562B1 (sr) 2015-02-27
SA99200617B1 (ar) 2006-06-24
JP5021711B2 (ja) 2012-09-12
HU229262B1 (en) 2013-10-28
USRE41356E1 (en) 2010-05-25
AR069583A2 (es) 2010-02-03
HRP20010102B1 (en) 2010-07-31
BR9917805B1 (pt) 2014-06-17
EP1105413B1 (en) 2009-04-29
BR9913646B1 (pt) 2014-12-02
MXPA01001423A (es) 2001-08-01
CY1109291T1 (el) 2014-07-02
EP2028186A2 (en) 2009-02-25
EA003906B1 (ru) 2003-10-30
US20020037998A1 (en) 2002-03-28
NO20010683D0 (no) 2001-02-09
TR200200129T2 (tr) 2002-06-21
EP2028186A3 (en) 2009-04-01
EE200100081A (et) 2002-08-15
CA2445938C (en) 2012-10-30
US6329417B1 (en) 2001-12-11
DK2028186T3 (da) 2013-03-25
NO328952B1 (no) 2010-06-28
WO2000009543A2 (en) 2000-02-24
AU5273199A (en) 2000-03-06
CA2338946C (en) 2010-10-12
PL346626A1 (en) 2002-02-25
HUP1300080A2 (enExample) 2002-04-29
AR020880A1 (es) 2002-06-05
PE20000949A1 (es) 2000-09-26
CY1113935T1 (el) 2016-07-27
KR100631439B1 (ko) 2006-10-09
SK2062001A3 (en) 2001-10-08
RS20090459A (sr) 2010-06-30
US6534523B1 (en) 2003-03-18
TWI250165B (en) 2006-03-01
ME00381B (me) 2011-10-10
ID27839A (id) 2001-04-26
ATE430158T1 (de) 2009-05-15
ZA200100971B (en) 2002-06-26
SA99200617A (ar) 2005-12-03
EA200100228A1 (ru) 2001-10-22
HUP0105144A3 (en) 2002-11-28
HU230701B1 (hu) 2017-10-30
MX261584B (es) 2008-10-22
CN101143892B (zh) 2010-12-08
HK1113164A1 (en) 2008-09-26
CN1323316A (zh) 2001-11-21
IN2001MU00127A (enExample) 2005-03-04
AR073428A2 (es) 2010-11-03
BG105232A (en) 2001-11-30
SI1105413T1 (sl) 2009-10-31
IN2007MU00706A (enExample) 2007-07-20
CN100339389C (zh) 2007-09-26
BG65738B1 (bg) 2009-09-30
USRE42164E1 (en) 2011-02-22
CA2338946A1 (en) 2000-02-24
IL196545A (en) 2012-06-28
EP1105413A2 (en) 2001-06-13
PH11999002002B1 (en) 2007-10-19
SI2028186T1 (sl) 2013-06-28
PL204850B1 (pl) 2010-02-26
DE69940817D1 (en) 2009-06-10
US6410531B1 (en) 2002-06-25
ES2326707T3 (es) 2009-10-16
AU769738B2 (en) 2004-02-05
USRE41894E1 (en) 2010-10-26
DK1105413T3 (da) 2009-08-17
KR20060083992A (ko) 2006-07-21
KR20010085363A (ko) 2001-09-07
MX257413B (es) 2008-05-27
JP4485685B2 (ja) 2010-06-23
PT2028186E (pt) 2013-03-27
CZ301268B6 (cs) 2009-12-30
HK1040085A1 (zh) 2002-05-24
TR200100432T2 (tr) 2001-09-21
USRE40525E1 (en) 2008-09-30
US6268207B1 (en) 2001-07-31
HUP0105144A2 (hu) 2002-04-29
NO336663B1 (no) 2015-10-12
NZ510396A (en) 2004-02-27
US6420380B2 (en) 2002-07-16
IL141012A (en) 2009-09-01
UA75026C2 (en) 2006-03-15
BR9913646A (pt) 2001-06-05
US6323180B1 (en) 2001-11-27
EE05517B1 (et) 2012-02-15
CA2445938A1 (en) 2000-02-24
HRP20010102A2 (en) 2002-02-28
CN101143892A (zh) 2008-03-19
EP2028186B1 (en) 2013-01-23
JP2010043124A (ja) 2010-02-25
BRPI9913646B8 (pt) 2021-05-25
WO2000009543A3 (en) 2000-05-25
MEP58508A (en) 2011-05-10
NO20100004L (no) 2001-04-02
KR100672229B1 (ko) 2007-02-28

Similar Documents

Publication Publication Date Title
BE2012C041I2 (enExample)
IN2001MU00127A (enExample)
BRPI9816295A2 (enExample)
BRPI9917863A2 (enExample)
IN190461B (enExample)
IN190970B (enExample)
CN3077125S (enExample)
CN3077998S (enExample)
CN3072760S (enExample)
CN3072761S (enExample)
CN3073550S (enExample)
CN3073964S (enExample)
CN3074052S (enExample)
CN3074053S (enExample)
CN3074158S (enExample)
CN3074547S (enExample)
CN3074692S (enExample)
CN3074906S (enExample)
CN3075297S (enExample)
CN3076419S (enExample)
CN3076421S (enExample)
CN3072688S (enExample)
CN3077095S (enExample)
BY4408C1 (enExample)
CN3077352S (enExample)